Barely Significant
← all excerpts

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Breast Cancer Res · 2010 · PMC2879572 · PMID 20398352

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

only marginally significantP < 0.001actually significant
For HP, a significant reduction was observed at 12 months but was only marginally significant at 24 months, probably due to the large between-patient variation (IQR = 13% at 24 months versus 6.7% at 12 months) (median decrease of BMD by -2.4%, P < 0.001 and -5.7%, P = 0.09, respectively); however, only 11 patients (22%) became osteopenic and 2 (4%) became osteoporotic.

also in 3,878 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.